Having trouble accessing articles? Reset your cache.

NICE backs broader use of AD drugs

The U.K.'s NICE issued an appraisal consultation document that would allow for the broadened use of four Alzheimer's disease (AD) drugs that were restricted in 2006 guidance.

Read the full 271 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE